<DOC>
	<DOCNO>NCT02709681</DOCNO>
	<brief_summary>This retrospective cohort study Sickle Cell Disease ( SCD ) patient attend 32 treatment center across Italy . The aim study report Italian experience use hydroxyurea large cohort SCD patient evaluate benefit safety intervention prevention management wide range clinical morbidity</brief_summary>
	<brief_title>Hydroxyurea Treatment Sickle Cell Disease</brief_title>
	<detailed_description>The indication hydroxyurea initiation 2-3 vaso-occlusive crisis and/or hospitalization last year . The study analyze demographic ( age gender ) , origin , genotype , clinical phenotype ( vaso-occlusive hemolytic ) , transfusion history ( include exchange ) , folic acid use , average laboratory value three year pre-hydroxyurea period post-hydroxyurea therapy include total hemoglobin level , fetal hemoglobin level , hemoglobin S level , white blood count , platelet count , lactate dehydrogenase level , total direct bilirubin level , aspartate alanine aminotransferase level , serum creatinine level . The incidence complication pre- post-hydroxyurea therapy also analyze include : stroke , silent cerebral infraction , acute chest syndrome , vaso-occlusive crisis , hospitalization , pulmonary hypertension , leg ulcer , bone necrosis , kidney injury . Safety data include adverse event report treat physician incidence malignancy death well pregnancy incident outcomes also point .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Sickle Cell Disease affect patient 23 vasoocclusive crisis and/or hospitalization last year Exclusion Criteria</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Hydroxyurea</keyword>
</DOC>